Home›Trial›NCT06161584
🔬NCT06161584ACTIVE NOT RECRUITING

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Study Summary

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Conditions
Geographic Atrophy
Interventions / Drugs
Pegcetacoplan
View on ClinicalTrials.gov ↗
Sponsor
APLS
Apellis Pharmaceuticals
Complement Inhibitors
D36/100
Study Details
Enrollment300 participants
Primary Completion—
Lead SponsorApellis Pharmaceuticals, Inc.
Data Retrieved2026-04-11 02:54:08.046086+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.